Yousef Shweihat, MD
Pulmonary Disease · Huntington, WVNPI 1407060015
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.0%), travel and lodging and education — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Pulmonx Corporation at 48.3% of the total. Reporting peaked in 2024 at $1,506 and has fallen 69.3% since, to $462 in 2025.
Across 134 payments — averaging $45.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pulmonx Corporation$3K
- Johnson & Johnson$1K
- AstraZeneca$429
- GSK$287
- Regeneron Healthcare Solutions, Inc.$237
- Boehringer Ingelheim$228
- plus $708 from 15 others
What the payments were for
- Travel & lodging$2,97148%
- Food & beverage$3,13051%
- Education$411%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pulmonx Corporation | 31 | $2,968 |
| Johnson & Johnson | 10 | $1,284 |
| AstraZeneca | 17 | $429 |
| GSK | 17 | $287 |
| Regeneron Healthcare Solutions, Inc. | 12 | $237 |
| Boehringer Ingelheim | 13 | $228 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $91 |
| Sanofi | 5 | $88 |
| Galvanize Therapeutics, Inc | 1 | $82 |
| United Therapeutics Corporation | 2 | $59 |
| Angiodynamics, Inc. | 1 | $59 |
| Insmed, Inc. | 3 | $56 |
| Baxter Healthcare | 3 | $52 |
| Advanced Respiratory, Inc | 2 | $45 |
| Circassia Inc. | 3 | $40 |
| Shire North American Group Inc | 2 | $37 |
| Novartis | 2 | $34 |
| Chiesi USA, Inc. | 1 | $17 |
| Verona Pharma, Inc. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,141 in reported general payments places this provider in the 80th percentile of 89 pulmonary disease providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TezspireTezepelumab-Ekko | 16 | $73,882 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 88 | $63,908 |
| NucalaMepolizumab | 13 | $45,144 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 56 | $28,382 |
| Spiriva RespimatTiotropium Bromide | 43 | $26,521 |
| Breo ElliptaFluticasone/Vilanterol | 36 | $18,926 |
| SymbicortBudesonide/Formoterol Fumarate | 68 | $17,738 |
| EliquisApixaban | 13 | $17,652 |
| Spiriva HandihalerTiotropium Bromide | 15 | $17,406 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $15,749 |
| Pirfenidone | 15 | $13,803 |
| Advair HfaFluticasone Propion/Salmeterol | 23 | $10,888 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 39 | $7,527 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 38 | $7,177 |
| Incruse ElliptaUmeclidinium Bromide | 15 | $6,501 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $287 | $162,861208 claims |
| AstraZenecaTezspire, Symbicort, Breztri Aerosphere | $429 | $107,368109 claims |
| Boehringer IngelheimSpiriva Respimat | $228 | $26,52143 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 89 pulmonary disease providers in West Virginia.
Other pulmonary disease in Huntington
- Fadi AlkhankanHuntington$5K
- Julian Lopez GarciaHuntington$5K
- Sigurdur SigurdarsonHuntington$5K
- Imran KhawajaHuntington$2K
- Amro Al-AstalHuntington$1K
- Melinda BeckerHuntington$776
- Melvin SaludesGlen Dale$255K
- Roger AbrahamsMorgantown$133K
- Maria BoustaniBeckley$95K
- Ramzi HaddadinBeckley$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.